Latest United States News

Infinity Metals has reported a sharply smaller FY2026 loss as it shifts its exploration focus towards the United States and Australia. The pivot follows rejection of its San José mining licence application, a A$2.25 million placement and a growing portfolio of early-stage copper, molybdenum and tin targets.

Silver Mines is seeking A$70 million from investors while agreeing to spend A$26 million to remove two private royalties from its Bowdens Silver Project. The strategy could simplify Bowdens’ economics, but the royalty deals depend on securing at least A$50 million in placement commitments and meeting approval conditions.

ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.

CMS has finalised higher Medicare inpatient reimbursement for EBR Systems’ WiSE System, lifting base payment rates by up to 93% from 1 October 2026. The change improves the commercial payment pathway, although its financial impact will depend on procedure volumes, hospital adoption and NTAP eligibility.

Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.

Anson Resources has signed a non-binding MoU covering a potential five-year lithium carbonate offtake with Wogen and possible project financing support from Xcelsior. The proposed supply could reach 6,000 tonnes of lithium carbonate equivalent a year, but deliveries remain dependent on Green River being financed, permitted and built.

Vectus Biosystems swung to a $1.56 million FY2026 profit, but the result was driven largely by the sale of its VB4-P5 compound for XORTX shares and warrants rather than recurring operations. The company is now directing its resources towards VB0004 while its auditor flags material uncertainty over ongoing funding.

CurveBeam AI has raised A$1.75 million through an oversubscribed SPP shortfall offer and placement, lifting its recent capital raised to A$7.36 million. The funds will support the HiRise China launch, product development, supply-chain preparation and working capital.

Atlas Arteria will pay securityholders an unfranked distribution of 20.0 Australian cents per stapled security for the six months to 30 June 2026. Securities go ex-entitlement on 23 September, with payment estimated for 7 October.

Ionic Rare Earths is pushing toward commercial magnet recycling in Belfast and the United States, but its FY2026 report flags a material uncertainty over its ability to continue as a going concern. The company reported a larger A$14.9 million loss and A$13.9 million in operating cash outflows, despite government support and new strategic partnerships.

Latrobe Magnesium has received a non-binding US$15 million Letter of Support from a confidential US financial institution for the feasibility study on its proposed 50 ktpa South Carolina magnesium plant. The funding remains conditional on matching finance, due diligence, approvals and definitive agreements.

Resonance Health has signed a 24-month alliance with London-based Image Analysis Group, making its quantitative MRI endpoints orderable across IAG’s global clinical-trial network. The opportunity is potentially significant, but remains uncontracted: two pilot studies come first, with no minimum revenue or volume commitments.